↓ Skip to main content

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

Overview of attention for article published in Endocrine, August 2011
Altmetric Badge

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours
Published in
Endocrine, August 2011
DOI 10.1007/s12020-011-9513-y
Pubmed ID
Authors

Kein-Leong Yim

Abstract

Approximately two-thirds of neuroendocrine tumours (NET) occur in the gastrointestinal tract and over 60% present with metastases. With greater insight into molecular pathways involved in tumour progression, opportunities are presented for the use of targeted therapies in NET. Although a wide array of targeted agents has been investigated, only a handful has emerged as forerunners from recent clinical trials. This literature review focuses on the use of anti-angiogenic monoclonal antibody bevacizumab, as well as small molecule inhibitors sunitinib and everolimus.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 38%
Researcher 1 13%
Other 1 13%
Student > Doctoral Student 1 13%
Unknown 2 25%
Readers by discipline Count As %
Medicine and Dentistry 4 50%
Agricultural and Biological Sciences 1 13%
Business, Management and Accounting 1 13%
Unknown 2 25%